Dr Camille Guillerey

PhD

Senior Research Officer

My Research

I am interested in blood cancers. These cancers include Lymphoma, Leukemia and Multiple Myeloma. I study how immune cells respond to these cancers and how we can harness this immune response to design better treatments for cancer patients.

Projects

Targeting Natural Killer cells in Acute Myeloid Leukemia

Suitable for Master, Honours or PhD students. Natural Killer (NK) cells are innate lymphocytes known for their potent cytotoxic activity against cancer cells. Clinical data indicate that NK cells play an important protective role in acute myeloid leukemia (AML). The project will used humanised mice (e.g. mice reconstituted with a human immune system) to design NK cell-targeting therapies for AML. 

Publications

  • O’Brien L., Guillerey, C. and Radford K. J. Can Dendritic Cell Vaccination Prevent Leukemia Relapse? Cancers, 2019, 11(6):875, doi: 10.3390/cancers11060875
  • Guillerey C, Nakamura K, Pichler C.A., Barkauskas D., Krumeich S., Stannard K., Miles K., Harjunpää H., Yu Y., Casey M., Doban A.I., Lazar M., Hartel G., Smith D., Vuckovic S., Teng W.L.M., Bergsagel P.L., Chesi M., Hill G.R., Martinet L., Smyth M.J. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight, 2019, doi: 10.1172/jci.insight.125932
  • Stannard K, Lemoine S, Waterhouse N, Vari F, Chatenoud L, Gandhi MK, Martinet L., Smyth MJ* and Guillerey C*. Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances. 2019 3:1681-1694; doi: https://doi.org/10.1182/bloodadvances.201803067
  • Guillerey C. Roles of cytotoxic and helper innate lymphoid cells in cancer. Mammalian Genome. 2018 Sep 3. doi: 10.1007/s00335-018-9781-4.
  • Guillerey C*, Harjunpää H*, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L and Smyth MJ.TIGIT immune checkpoint blockade restores CD8+ T cell immunity against multiple myeloma. Blood. 2018 Jul 9. pii: blood-2018-01-825265. doi: 10.1182/blood-2018-01-825265.
  • Oberkampf M*, Guillerey C*, Mouriès J*, Rosenbaum P, Fayolle C, Bobard A, Savina A, Ogier-Denis E, Enninga J, Amigorena S, Leclerc C and Dadaglio G. Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells, Nature Communications, 2018 Jun 8;9(1):2241. doi: 10.1038/s41467-018-04686-8.​
  • Guillerey C, Huntington, ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nature Immunology, 2016 Aug 19; 17(9):1025-36.
  • Guillerey C, Nakamura K, Vuckovic S, Hill GF and Smyth MJ, Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies, Cellular and Molecular Life Sciences, 2016 Jan 22; 73(8):1569-89.
  • Guillerey C and Smyth MJ; NK cells and Cancer Immunoediting, Current Topics in Microbiology and Immunology, 2016; 395:115-45.
  • Guillerey C*, De Andrade LF*, Vuckovic S, Miles K, Ngiow SF, Yong MCR, Teng MWL, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, S­myth MJ*, Martinet L* Immunosurveillance and therapy of multiple myeloma is CD226-dependent; Journal of Clinical Investigation, 2015 May 1;125(5):2077-89.
  • Guillerey C*, Chow MT*, Miles K, Olver S, Sceneay J, Takeda K, Moller A, S­myth MJ; Toll-Like Receptor 3 regulates NK cell responses to cytokines and controls metastasis;  OncoImmunology, 2015 April 2; 4(9):e1027468.
  • Guillerey C, Mouriès J, Polo G, Doyen N, Law H, Chan S, Kastner P, Leclerc C, Dadaglio G; Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice; Blood; 2012 Jul 5;120(1):90-9.

Connect

ORCIDGoogle Scholar